Both papilmod and dasatinib are protein kinase inhibitors commonly employed in the treatment of rheumatoid arthritis and chronic myelogenous leukemia, respectively. The gene discussed is WEE1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.